Extended Data Fig. 3: Soluble MAdCAM-1 linear distribution.
From: Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
a,b, Kaplan–Meier survival estimates of progression-free survival (PFS; a) and overall survival (OS; b) in patients from the JAVELIN Renal 101 trial showing both superposing curves for the intention-to-treat population and in the subset of patients analyzed in the biomarker ancillary study cohort from the trial, across both treatment arms. Risk tables indicate the number of patients at risk at each time point. c,d, Kaplan–Meier survival estimates of PFS (c) and OS (d) stratified by sMAdCAM-1 concentrations in the JAVELIN Renal 101 trial. Patients were dichotomized using a threshold of 180 ng/mL into low (≤180 ng/mL) and high (>180 nng/mL) sMAdCAM-1 groups. Survival differences were assessed using the log-rank test; P values are shown. Risk tables indicate the number of patients at risk at each time point.
